High vaccine efficacy seen against RSV A and B subtypes, across age groups among those aged 60 years and older, and for those with coexisting conditions.
Minor changes and additions to annual ACIP recommendations affected vaccines for COVID-19; dengue fever; pneumococcal disease; and measles, mumps, and rubella.
Hepatitis B Vaccines Market – Growth, Future Prospects and Competitive Analysis, 2017 – 2025 the global hepatitis B vaccines market was valued at US$ 1.39 Bn in 2016, and is expected to reach US$ 1.89 Bn by 2025, expanding at a CAGR of 3.5% from 2017 to 2025. Browse Full Report Click Here: http://www.acutemarketreports.com/report/hepatitis-b-vaccines-market Market Insights Hepatitis B is life threatening liver infection. Hepatitis B vaccines market is rapidly growing as it is effective in prevention of infection than any other treatment options. Some factors such as increased awareness of hepatitis B infection prevention, government initiatives in conduction of routine immunization…